Access in all areas? A round up of developments in market access and health technology assessment: part 8

In this update, we discuss the pricing paradox of combination therapies in health technology assessment; examine the Inflation Reduction Act's impact on pharmaceutical innovation and analyze the revised Dutch economic evaluation guidelines.